H1N1 like vaccine coated nanopatch - Vaxxas
Alternative Names: A/California/7/2009-(H1N1)-like-vaccine-coated-nanopatch; A/Michigan/45/2015(H1N1)-like-vaccine coated micro-projection array patch; A/Singapore/GP1908/2015 vaccine coated micro-projection array patch; H1N1 vaccine nanopatch - Vaxxas; HD-MAP Influenza A virus vaccine - Vaxxas; Influenza A virus H1N1 subtype vaccine - Vaxxas; Influenza A virus H1N1 vaccine nanopatch - VaxxasLatest Information Update: 08 Apr 2025
At a glance
- Originator Vaxxas
- Class Influenza A virus H1N1 vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Influenza A virus H1N1 subtype
Most Recent Events
- 28 Mar 2025 Vaxxas has patent protection for high-density microarray patch (HD-MAP) vaccination technology in Europe, Asia and Australia
- 28 Mar 2025 Vaxxas has patent protection for high-density microarray patch (HD-MAP) vaccination technology in USA
- 28 Apr 2023 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(Prevention) in Australia (Transdermal, Patch)